JNJ-7446 / J&J - LARVOL DELTA

JNJ-95437446: Discovery and preclinical characterization of an amivantamab-based EGFR/MET-ADC for solid tumor indications (AACR 2026) - "Abstract is embargoed at this time."

ADC • Late-breaking abstract • Preclinical • Oncology • Solid Tumor • EGFR

95437446LUC1001: A Phase 1 study of JNJ-95437446 in participants with advanced-stage solid tumors (clinicaltrialsregister.eu) - P1 | N=52 | Recruiting | Sponsor: Janssen Cilag International

New P1 trial • Head and Neck Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma of Head and Neck

A Study of JNJ-95437446 in Participants With Advanced-Stage Solid Tumors (clinicaltrials.gov) - P1 | N=380 | Recruiting | Sponsor: Janssen Research & Development, LLC | Trial completion date: Nov 2027 ➔ Apr 2028

Trial completion date • Colorectal Cancer • Oncology • Solid Tumor